Margaret S. Lee

Dr. Lee has nearly two decades of industry experience driving the discovery and development of novel drug candidates in multiple therapeutic areas and is a recognized leader in T-type calcium channel biology. Prior to joining Cavion, she was VP of Research and Translational Development at Karyopharm, where she led the development of non-clinical and clinical-stage pipeline candidates in oncology, infectious, autoimmune, and neurodegenerative diseases. Prior to Karyopharm, she was VP of Research and Translational Medicine at Zalicus Inc. (formerly CombinatoRx), where she led the discovery and development of single-agent and combination drug candidates including the development of a novel T-type calcium channel modulator. Dr. Lee received her B.S. in Biology from Southampton College of Long Island University, her Ph.D. from Tufts University Sackler School, and conducted her postdoctoral research at Dana-Farber Cancer Institute/Harvard Medical School. She is an author of over 30 peer-reviewed publications and book chapters and an inventor of multiple patent applications and issued patents.